![5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine](https://static.cymitquimica.com/cas-image/549834-5-6-3-methoxyoxetan-3-yl-4-morpholinothieno-32-d-pyrimidin-2-yl-pyrimidin-2-amine.png)
CAS: 1394076-92-6 - 5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | 5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine REF: IN-DA009CI2CAS: 1394076-92-6 | 98% | 138,00 €~562,00 € | Mar 07 Ene 25 |
 | GNE-317 REF: TM-T6845CAS: 1394076-92-6 | 99.08% - 99.42% | 39,00 €~623,00 € | Mar 14 Ene 25 |
 | GNE-317 REF: 3D-UFC07692CAS: 1394076-92-6 | Min. 95% | A consultar | Mar 18 Feb 25 |
![5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine](https://static.cymitquimica.com/products/IN/thumb/DA009CI2.jpg)
5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine
CAS:1394076-92-6
Fórmula:
C19H22N6O3S
Pureza:
98%
Forma y color:
Solid
Peso molecular:
414.4814
Ref: IN-DA009CI2
| 5mg | 138,00 € | ||
| 10mg | 151,00 € | ||
| 50mg | 178,00 € | ||
| 100mg | 299,00 € |
Entrega estimada en Estados Unidos, el Martes 7 de Enero de 2025
GNE-317
CAS:1394076-92-6
GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
Fórmula:
C19H22N6O3S
Pureza:
99.08% - 99.42%
Forma y color:
Solid
Peso molecular:
414.48
Ref: TM-T6845
| 1mg | 39,00 € | ||
| 2mg | 51,00 € | ||
| 5mg | 82,00 € | ||
| 10mg | 118,00 € | ||
| 25mg | 207,00 € | ||
| 50mg | 342,00 € | ||
| 100mg | 426,00 € | ||
| 200mg | 623,00 € | ||
| 1mL*10mM (DMSO) | 92,00 € |
Entrega estimada en Estados Unidos, el Martes 14 de Enero de 2025
GNE-317
CAS:1394076-92-6
GNE-317 is a cancer therapeutic that inhibits the activity of CDK4/6 and is currently in …
Fórmula:
C19H22N6O3S
Pureza:
Min. 95%
Peso molecular:
414.48 g/mol
Ref: 3D-UFC07692
| 50mg | A consultar | ||
| 100mg | A consultar |
Entrega estimada en Estados Unidos, el Martes 18 de Febrero de 2025
